newsfilter
← Latest News
GlobeNewswire·

Satsuma Pharmaceuticals Reports Third Quarter 2022 Financial Results and Recent Business Highlights

- On track to report topline results from STS101 SUMMIT Phase 3 efficacy trial in November 2022; NDA submission planned in Q1 2023 - - $64.4 million in cash, cash equivalents and marketable securities as of September